NPM1 and acute myeloid leukemia: More recently, the ELN has re-classified FLT3-mutated AML such that patients with FLT3-ITDlow (AR < 0.5), normal cytogenetics, and mutated NPM1 are considered low risk, suggesting these patients may have good prognosis without HCT (138).